Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 101

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 101
---
 public accounting firm, and reviewing, with management and the     
 independent registered public accounting firm, our interim and year-end results of operations;                                        |
| ● | developing                                                                                                                            
 procedures for employees to submit concerns anonymously about questionable accounting or audit matters;                               |
| ● | reviewing                                                                                                                             
 our policies on risk assessment and risk management;                                                                                  |
| ● | reviewing                                                                                                                             
 related party transactions;                                                                                                           |
| ● | reviewing                                                                                                                             
 and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public 
 accounting firm; and                                                                                                                  |
| ● | assisting                                                                                                                             
 our board of directors in monitoring the performance of our internal audit function.                                                  |

Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.

Compensation Committee

The Compensation Committee was initially established upon the effectiveness of our initial public offering on February 9, 2024. As of December 2024, the Compensation Committee consists of Dr. Matthew P. Del Giudice (Chair), and Mr. Edward MacPherson. Dr. Matthew P. Del Giudice succeeded Talhia Tuck as Chair of the Compensation Committee following her resignation, along with Bradley Kroenig, from the Board of Directors in August 2024. Each member of the committee meets the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations. Each member is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act, or Rule 16b-3.

In arriving at these determinations, our board of directors examined all factors relevant to determining whether any compensation committee member had a relationship to us that is material to that member’s ability to be independent from management in connection with carrying out such member’s duties as a compensation committee member.

The compensation committee’s main purpose is to review and recommend policies relating to compensation and benefits of our officers and employees. Our compensation committee is responsible for, among other things:

| ● | reviewing,                                                                                                                                
 approving, and determining, or making recommendations to our board of directors regarding, the compensation and compensation arrangements 
 of our executive officers;                                                                                                                |
| ● | administering                                                                                                                             
 our equity compensation plans;                                                                                                            |
| ● | reviewing                                                                                                                                 
 and approving, or making recommendations to our board of directors regarding